# OnCo record lume-meso (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/lume-meso/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "lume-meso", "NCT01907100" ;
  schema:name "LUME-Meso"@en ;
  schema:description "LUME-Meso randomised 458 patients with epithelioid pleural mesothelioma to first-line cisplatin and pemetrexed with nintedanib or placebo. The phase 2 progression signal for the multi-kinase inhibitor vanished in phase 3, with no delay in progression and no gain in life, a lesson in the unreliability of small phase 2 signals in this disease."@en ;
  schema:url <https://onco.cc/trials/lume-meso/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01907100> ;
  onco:status "negative" ;
  onco:tag "lesson:phase-2-pfs-signal" ;
  onco:phase "2/3" ;
  schema:startDate "2013-09-19" ;
  onco:cancers <https://onco.cc/cancers/mesothelioma/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/nintedanib/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/boehringer-ingelheim/> .